These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38127441)

  • 1. Hyperactive mTORC1 in lung mesenchyme induces endothelial cell dysfunction and pulmonary vascular remodeling.
    Lin SM; Rue R; Mukhitov AR; Goel A; Basil MC; Obraztsova K; Babu A; Crnkovic S; Ledwell OA; Ferguson LT; Planer JD; Nottingham AN; Vanka KS; Smith CJ; Cantu E; Kwapiszewska G; Morrisey EE; Evans JF; Krymskaya VP
    J Clin Invest; 2023 Dec; 134(4):. PubMed ID: 38127441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTORC1 activation in lung mesenchyme drives sex- and age-dependent pulmonary structure and function decline.
    Obraztsova K; Basil MC; Rue R; Sivakumar A; Lin SM; Mukhitov AR; Gritsiuta AI; Evans JF; Kopp M; Katzen J; Robichaud A; Atochina-Vasserman EN; Li S; Carl J; Babu A; Morley MP; Cantu E; Beers MF; Frank DB; Morrisey EE; Krymskaya VP
    Nat Commun; 2020 Nov; 11(1):5640. PubMed ID: 33159078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
    Lu Y; Liu X; Zhang E; Kopras EJ; Smith EP; Astreinidis A; Li C; Leung YK; Ho SM; Yu JJ
    PLoS One; 2020; 15(2):e0228894. PubMed ID: 32078667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
    Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphangioleiomyomatosis: a metastatic lung disease.
    Kundu N; Holz MK
    Am J Physiol Cell Physiol; 2023 Feb; 324(2):C320-C326. PubMed ID: 36571446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
    Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
    Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
    Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
    Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway.
    Feng Y; Li T; Li Y; Lin Z; Han X; Pei X; Zhang Y; Li F; Yang J; Shao D; Li C
    Clin Transl Med; 2023 Jul; 13(7):e1333. PubMed ID: 37478294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
    Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
    Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
    Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis.
    Gibbons E; Taya M; Wu H; Lopa SH; Moss J; Henske EP; McCormack FX; Hammes SR
    Endocr Relat Cancer; 2024 Jun; 31(6):. PubMed ID: 38614127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.
    Steagall WK; Pacheco-Rodriguez G; Glasgow CG; Ikeda Y; Lin JP; Zheng G; Moss J
    Am J Pathol; 2013 Sep; 183(3):938-50. PubMed ID: 23867796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex.
    Astrinidis A; Li C; Zhang EY; Zhao X; Zhao S; Guo M; Olatoke T; Mattam U; Huang R; Zhang AG; Pitstick L; Kopras EJ; Gupta N; Jandarov R; Smith EP; Fugate E; Lindquist D; Markiewski MM; Karbowniczek M; Wikenheiser-Brokamp KA; Setchell KDR; McCormack FX; Xu Y; Yu JJ
    JCI Insight; 2023 May; 8(9):. PubMed ID: 36927688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
    Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
    Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells.
    Valianou M; Filippidou N; Johnson DL; Vogel P; Zhang EY; Liu X; Lu Y; Yu JJ; Bissler JJ; Astrinidis A
    Sci Rep; 2019 Feb; 9(1):3015. PubMed ID: 30816188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
    Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
    IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.
    Li C; Liu X; Liu Y; Zhang E; Medepalli K; Masuda K; Li N; Wikenheiser-Brokamp KA; Osterburg A; Borchers MT; Kopras EJ; Plas DR; Sun J; Franz DN; Capal JK; Mays M; Sun Y; Kwiatkowski DJ; Alayev A; Holz MK; Krueger DA; Siroky BJ; Yu JJ
    Mol Cancer Res; 2017 Oct; 15(10):1318-1330. PubMed ID: 28710231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.